Cyclopharm Limited (CYC:ASX)

$2.60

right-arrow Created with Sketch. 0 (0%)
MCAP $242.7M
Last trade 11.46am 26/02/2021 20mins delayed

Latest Announcements

25/02/2021CYCCyclopharm Limited
25/02/2021 Price SensitivePSCYCCyclopharm Limited
25/02/2021 Price SensitivePSCYCCyclopharm Limited
24/02/2021CYCCyclopharm Limited
24/02/2021CYCCyclopharm Limited
19/02/2021CYCCyclopharm Limited
181
MCap
19/02/2021CYCCyclopharm Limited
72
MCap
17/02/2021CYCCyclopharm Limited

Company Overview

Cyclopharm Limited is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. The Company operates in two business segments: Technegas segment and Molecular imaging segment. The Technegas segment is a supplier of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The Molecular Imaging segment produces radiopharmaceuticals used by physicians in the detection of cancer, neurological disorders and cardiac diseases. The Company offers Technegas for lung imaging, and Molecular Imaging/Positron Emission Tomography radiopharmaceuticals, which are used in cancer, brain and cardiac imaging. The Company formed a joint venture with Alfred Health Solutions and Macquarie University Hospital to provide various imaging services on-site at the hospital. The Company's Ultralute is a device that extends the useful life of Molybdenum-99 (Mo-99) generators.

CYC in the news

Search Previous Announcements